DSP-0390 clinical trials
Also written DSP-0390.
How each study uses DSP-0390 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the DSP-0390 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- DSP-0390
- 3
Studies by the year they started
3 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
Washington University School of Medicine (2) · Sumitomo Pharma America, Inc. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test DSP-0390.
- Apr 2027Window of Opportunity Study of DSP-0390 in GliomasEarly Phase 1 · Washington University School of Medicine
- Sep 2027Study of DSP-0390 in Patients With Recurrent High-Grade GliomaEarly Phase 1 · Sumitomo Pharma America, Inc.
Studies
Open first, then newest update. How each study uses DSP-0390 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- DSP-0390 in Combination With Atezolizumab for Small Cell Lung CancerRecruitingPhase 1Washington University School of MedicineNCT07545954Written as DSP-0390
- Window of Opportunity Study of DSP-0390 in GliomasRecruitingEarly Phase 1Washington University School of MedicineNCT06636162Written as DSP-0390
- Study of DSP-0390 in Patients With Recurrent High-Grade GliomaActive, not recruitingEarly Phase 1Sumitomo Pharma America, Inc.NCT05023551Written as DSP-0390
Codes
What other systems call DSP-0390 · ClinicalTrials.gg INT017785
- UNII (FDA) RB55ZW48XGDSP-0390One source FDA
- NCI Thesaurus C187142EBP Inhibitor DSP-0390One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | RB55ZW48XG | DSP-0390 | One source FDA |
| NCI Thesaurus | C187142 | EBP Inhibitor DSP-0390 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.